Non-muscle Invasive Bladder Cancer Clinical Trials in New York, New York

6 studies are recruiting for non-muscle invasive bladder cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

   This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 participants who do n…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   5 in total

   Run by

   John Sfakianos

   See if you can join NCT06503614 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

   The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York

   Locations

   68 in total

   Run by

   Pfizer

   See if you can join NCT07206225 on ClinicalTrials.gov

3. Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

   TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-0…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Laura & Isaac Perlmutter Cancer Center - NYU Langone Health, New York, New York

   Locations

   78 in total

   Run by

   Protara Therapeutics

   See if you can join NCT05951179 on ClinicalTrials.gov

4. A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

   The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or…

   Stage

   Phase 3

   Ages

   21 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   9 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06929286 on ClinicalTrials.gov

5. Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

   The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder. The researchers will test different doses of 2141-V11 to see which dose is safest in p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05126472 on ClinicalTrials.gov

6. LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

   This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, fo…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

   Locations

   102 in total

   Run by

   enGene, Inc.

   See if you can join NCT04752722 on ClinicalTrials.gov